A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121).
Publication/Presentation Date
12-15-2011
Abstract
Based on its potential role in adult myelodysplastic syndrome (MDS), the Children's Oncology Group (COG) embarked on a phase II study using amifostine in pediatric MDS (WHO 2001 criteria) patients. Responses were evaluated after two cycles. Ten patients were enrolled; five were deemed ineligible, and four withdrew after the first course. Only one patient completed two courses, and was found to be in complete remission. The study was closed after being open for 2 years due to slow accrual. Studying a rare disease like MDS may pose insurmountable obstacles even in a large clinical trials group such as COG, in part because of the changing definitions of MDS and the rarity of adult type MDS in children. The role of amifostine in pediatric MDS was not known at the time of study.
Volume
57
Issue
7
First Page
1230
Last Page
1232
ISSN
1545-5017
Published In/Presented At
Mathew, P., Gerbing, R., Alonzo, T. A., Wallas, T., Gong, J. Z., Jasty, R., Jorstad, D. T., Raimondi, S. C., Chavez, C. M., Eisenberg, N. L., Hirsch, B., Gamis, A., Smith, F. O., & Arceci, R. J. (2011). A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121). Pediatric blood & cancer, 57(7), 1230–1232. https://doi.org/10.1002/pbc.23164
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
21681928
Department(s)
Administration and Leadership
Document Type
Article